Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AL3818

Phase 3Small molecule

AAdvenchen Laboratories, LLC

AL3818 is one of 105 small molecule programs targeting Interaction. It is currently in Phase 3.

3

Indications

7

Total Trials

4

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

InteractionNot yet recruiting

Alveolar Soft Part SarcomaRecruiting

Solid TumorsActive, not recruiting

InteractionPhase 1

Not yet recruiting

Alveolar Soft Part SarcomaPhase 3

Recruiting

Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Lynparza

Lenvima

Taxol

Gemzar

Johnson & Johnson

Opdivo

Bristol-Myers Squibb

Beyfortus

Fludara

Camptosar

Taxotere

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Interaction

NCT07438886

Q1 2028

Phase 1/2Active, not recruiting

Solid Tumors

NCT04165330

Q4 2028

Phase 3Recruiting

Alveolar Soft Part Sarcoma

NCT03016819

Q3 2031

PreclinicalNot yet recruiting

Endometrial Neoplasms

NCT07811297

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Terminated·AAdvenchen Laboratories, LLC·Phase 1/2·NCT02558348·12 enrolled

Alveolar Soft Part Sarcoma1 trial

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Recruiting·AAdvenchen Laboratories, LLC·Phase 3·NCT03016819·325 enrolled

Solid Tumors1 trial

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting·SSarcoma Oncology Research Center, LLC·Phase 1/2·NCT04165330·56 enrolled

Interaction1 trial

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Not yet recruiting·AAdvenchen Laboratories Nanjing Ltd.·Phase 1·NCT07438886·16 enrolled

Cervical Carcinoma1 trial

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Unknown status·AAdvenchen Laboratories, LLC·Phase 3·NCT02584478·294 enrolled

2 more indications

Trial1 trial

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Available·AAdvenchen Laboratories, LLC··NCT05612191

Endometrial Neoplasms1 trial

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

Not yet recruiting·AAdvenchen Pharmaceuticals, LLC.·Preclinical·NCT07811297·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AL3818. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AL3818 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AL3818. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advenchen Laboratories, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvenchen Laboratories, LLC

Related News